BRM.DE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	6 585.00
Średni wolumen	2 534.00
Kapitalizacja rynkowa	88.44B
EPS	€0 ( 2024-04-25 )
Następna data zysków	( €0 ) 2024-07-26
Last Dividend	€0.570 ( 2023-07-06 )
Next Dividend	€0 ( N/A )
P/E	12.10
ATR14	€0.0880 (0.21%)

Wolumen Korelacja

Długi: -0.06 (neutral)

Krótki: -0.46 (neutral)

Signal:(65.485) Neutral

Bristol-Myers Squibb Co Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bristol-Myers Squibb Co Korelacja - Waluta/Towar

0.50
( weak )

0.70
( moderate )

0.57
( weak )

0.71
( moderate )

-0.74
( moderate negative )

-0.78
( moderate negative )

Bristol-Myers Squibb Co Finanse

Annual	2023
Przychody:	€45.01B
Zysk brutto:	€34.31B (76.24 %)
EPS:	€3.88

FY	2023
Przychody:	€45.01B
Zysk brutto:	€34.31B (76.24 %)
EPS:	€3.88

FY	2022
Przychody:	€46.16B
Zysk brutto:	€36.02B (78.04 %)
EPS:	€2.97

FY	2021
Przychody:	€46.39B
Zysk brutto:	€36.45B (78.57 %)
EPS:	€3.15

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0.540 (N/A)	€0.570 (N/A)	€0.570 (N/A)	€0.570 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Bristol-Myers Squibb Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.68 - Stable (13.63%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.215	1999-06-30
Last Dividend	€0.570	2023-07-06
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	97	--
Total Paid Out	€33.94	--
Avg. Dividend % Per Year	0.00%	--
Score	4.93	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.68
Div. Directional Score	8.19	--

Next Divdend (Est)
(2024-05-08)

€0.580 Estimate 21.49 %

Dividend Stability

0.57 Average

Dividend Score

4.93

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
PTTG.F	Ex Dividend Knight	2023-08-15	Semi-Annually	0.00%
BRM.DE	Ex Dividend Knight	2023-07-06	Quarterly	0.00%
INN1.DE	Ex Dividend Junior	2023-08-07	Semi-Annually	0.00%
STO3.DE	Ex Dividend Junior	2023-06-22	Annually	0.00%
DAR.DE	No Dividend Player	2023-07-03	Annually	0.00%
LUS1.DE	Ex Dividend Junior	2023-06-23	Annually	0.00%
4I1.DE	Ex Dividend Knight	2023-09-26	Quarterly	0.00%
VAS.DE	Ex Dividend Junior	2023-07-13	Annually	0.00%
ERCB.DE	Ex Dividend Junior	2023-09-28	Annually	0.00%
NVD.DE	Ex Dividend Knight	2023-09-06	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.178	1.500	6.43	9.65	[0 - 0.5]
returnOnAssetsTTM	0.0843	1.200	7.19	8.63	[0 - 0.3]
returnOnEquityTTM	0.263	1.500	8.19	10.00	[0.1 - 1]
payoutRatioTTM	0.591	-1.000	4.09	-4.09	[0 - 1]
currentRatioTTM	1.427	0.800	7.86	6.29	[1 - 3]
quickRatioTTM	1.237	0.800	7.43	5.94	[0.8 - 2.5]
cashRatioTTM	0.515	1.500	8.25	10.00	[0.2 - 2]
debtRatioTTM	0.436	-1.500	2.74	-4.11	[0 - 0.6]
interestCoverageTTM	8.08	1.000	8.12	8.12	[3 - 30]
operatingCashFlowPerShareTTM	6.82	2.00	7.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.23	2.00	6.89	10.00	[0 - 20]
debtEquityRatioTTM	1.409	-1.500	4.36	-6.55	[0 - 2.5]
grossProfitMarginTTM	0.762	1.000	0.627	0.627	[0.2 - 0.8]
operatingProfitMarginTTM	0.209	1.000	7.82	7.82	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.334	1.000	9.25	9.25	[0.2 - 2]
assetTurnoverTTM	0.473	0.800	-0.180	-0.144	[0.5 - 2]
Total Score				10.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.47	1.000	8.94	0	[1 - 100]
returnOnEquityTTM	0.263	2.50	8.84	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.23	2.00	7.92	10.00	[0 - 30]
dividendYielPercentageTTM	1.258	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.82	2.00	7.73	10.00	[0 - 30]
payoutRatioTTM	0.591	1.500	4.09	-4.09	[0 - 1]
pegRatioTTM	0.194	1.500	-2.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.308	1.000	4.80	0	[0.1 - 0.5]
Total Score				5.68

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.